Merck Expects Underlying Operating Expenses To Increase Mid- To High-Single Digits Next Year; For Keytruda Expecting Moderating Growth As We Approach Peak Revenues For Certain Approved Indications; For Keytruda, Expecting German Market To Be Impacted By Policy Dynamics; Expecting Keytruda & Winrevair Benefit To Fully Unwind In Q4; Majority Of Vaccines Benefit, Primarily Gardasil, To Unwind In 2027

Benzinga · 3d ago

https://www.merck.com/wp-content/uploads/sites/124/2026/10/3Q26-Merck-Earnings-Presentation.pdf